
Global Iron Deficiency Anemia Therapy Market Size study, by Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy), Age Group, End-user, and Regional Forecasts 2022–2032
Description
The Global Iron Deficiency Anemia Therapy Market is valued at approximately USD 4.83 billion in 2023 and is poised to expand at a healthy CAGR of more than 7.60% over the forecast period 2024–2032. Iron deficiency anemia (IDA), a condition that affects oxygen transport in the body due to insufficient iron levels, continues to be a widespread and undertreated health challenge. The growing prevalence of nutritional deficiencies, pregnancy-related anemia, chronic blood loss, and gastrointestinal disorders is significantly influencing market growth. The increasing demand for therapeutic interventions that range from oral supplementation to intravenous iron therapies is reshaping how healthcare systems and patients approach IDA management, especially in emerging markets and underserved populations.
Over the years, oral iron therapy has remained the first-line treatment for mild to moderate cases of IDA owing to its cost-effectiveness and ease of administration. However, patient non-compliance due to gastrointestinal side effects has driven a surge in preference for parenteral iron therapies, which offer faster iron repletion and improved bioavailability. Innovations such as iron polymaltose complexes and ferric carboxymaltose are being strategically deployed to address chronic conditions like chronic kidney disease (CKD) and inflammatory bowel disease (IBD), where oral iron absorption is often compromised. Alongside these developments, pediatric and geriatric populations are receiving increasing attention with tailored formulations that cater to specific metabolic and physiological requirements.
A growing body of clinical guidelines advocating for early intervention and iron profiling is prompting a paradigm shift from symptomatic treatment to proactive screening and individualized therapy. As awareness campaigns and nutrition-based public health programs expand, iron therapy is gaining acceptance in broader demographics, including menstruating women, adolescents, and postpartum mothers. Healthcare providers are now emphasizing patient-centric approaches that optimize dosing frequency and minimize side effects, while pharmaceutical manufacturers are accelerating R&D investments into next-generation delivery mechanisms. Digital health integration is further enhancing adherence monitoring and outcome tracking, particularly in high-risk patient cohorts.
Regionally, North America commands a significant share of the global market due to its well-structured healthcare infrastructure, reimbursement frameworks, and rising prevalence of chronic ailments such as CKD and cancer-associated anemia. Europe follows closely, buoyed by national anemia reduction initiatives and high awareness levels among women and children. Meanwhile, the Asia Pacific region is witnessing the fastest growth trajectory, driven by a large anemic population base, rapid urbanization, and increased government funding for maternal and child health. Countries like India and China are particularly pivotal, with their extensive rural outreach programs and efforts to reduce micronutrient malnutrition.
Major market player included in this report are:
• Sanofi S.A.
• Vifor Pharma Ltd.
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• AMAG Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Mylan N.V.
• Zydus Lifesciences Ltd.
• Bayer AG
• Cipla Ltd.
• Akebia Therapeutics, Inc.
• Rockwell Medical, Inc.
The detailed segments and sub-segment of the market are explained below:
By Therapy Type
• Oral Iron Therapy
• Parenteral Iron Therapy
By Age Group
• Pediatric
• Adult
• Geriatric
By End-user
• Hospitals
• Clinics
• Homecare
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Over the years, oral iron therapy has remained the first-line treatment for mild to moderate cases of IDA owing to its cost-effectiveness and ease of administration. However, patient non-compliance due to gastrointestinal side effects has driven a surge in preference for parenteral iron therapies, which offer faster iron repletion and improved bioavailability. Innovations such as iron polymaltose complexes and ferric carboxymaltose are being strategically deployed to address chronic conditions like chronic kidney disease (CKD) and inflammatory bowel disease (IBD), where oral iron absorption is often compromised. Alongside these developments, pediatric and geriatric populations are receiving increasing attention with tailored formulations that cater to specific metabolic and physiological requirements.
A growing body of clinical guidelines advocating for early intervention and iron profiling is prompting a paradigm shift from symptomatic treatment to proactive screening and individualized therapy. As awareness campaigns and nutrition-based public health programs expand, iron therapy is gaining acceptance in broader demographics, including menstruating women, adolescents, and postpartum mothers. Healthcare providers are now emphasizing patient-centric approaches that optimize dosing frequency and minimize side effects, while pharmaceutical manufacturers are accelerating R&D investments into next-generation delivery mechanisms. Digital health integration is further enhancing adherence monitoring and outcome tracking, particularly in high-risk patient cohorts.
Regionally, North America commands a significant share of the global market due to its well-structured healthcare infrastructure, reimbursement frameworks, and rising prevalence of chronic ailments such as CKD and cancer-associated anemia. Europe follows closely, buoyed by national anemia reduction initiatives and high awareness levels among women and children. Meanwhile, the Asia Pacific region is witnessing the fastest growth trajectory, driven by a large anemic population base, rapid urbanization, and increased government funding for maternal and child health. Countries like India and China are particularly pivotal, with their extensive rural outreach programs and efforts to reduce micronutrient malnutrition.
Major market player included in this report are:
• Sanofi S.A.
• Vifor Pharma Ltd.
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• AMAG Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Mylan N.V.
• Zydus Lifesciences Ltd.
• Bayer AG
• Cipla Ltd.
• Akebia Therapeutics, Inc.
• Rockwell Medical, Inc.
The detailed segments and sub-segment of the market are explained below:
By Therapy Type
• Oral Iron Therapy
• Parenteral Iron Therapy
By Age Group
• Pediatric
• Adult
• Geriatric
By End-user
• Hospitals
• Clinics
• Homecare
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Table of Contents
285 Pages
- Chapter 1. Global Iron Deficiency Anemia Therapy Market Executive Summary
- 1.1. Global Iron Deficiency Anemia Therapy Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Therapy Type
- 1.3.2. By End-user
- 1.4. Key Trends
- 1.5. Reimbursement Impact
- 1.6. Analyst Recommendation & Conclusion
- Chapter 2. Global Iron Deficiency Anemia Therapy Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Patient Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Screening & Diagnosis Trends
- 2.3.4.2. Treatment Guidelines
- 2.3.4.3. Patient Awareness & Compliance
- 2.3.4.4. Digital Health Integration
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
- Chapter 3. Global Iron Deficiency Anemia Therapy Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising Prevalence of Nutritional Deficiencies & Anemia
- 3.1.2. Shift Towards Parenteral Iron for Improved Compliance
- 3.1.3. Adoption of Early Screening & Individualized Therapy Guidelines
- 3.2. Market Challenges
- 3.2.1. Gastrointestinal Side Effects & Patient Non-compliance
- 3.2.2. Regulatory Hurdles & Cost Barriers in Emerging Economies
- 3.3. Market Opportunities
- 3.3.1. Digital Adherence Monitoring & Telehealth-Enabled Care
- 3.3.2. Tailored Pediatric & Geriatric Formulations
- 3.3.3. Expansion through Public Health Programs in Asia Pacific
- Chapter 4. Global Iron Deficiency Anemia Therapy Market Industry Analysis
- 4.1. Porter’s 5 Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
- Chapter 5. Global Iron Deficiency Anemia Therapy Market Size & Forecasts by Therapy Type 2022–2032
- 5.1. Segment Dashboard
- 5.2. Global Market: Oral Iron Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.3. Global Market: Parenteral Iron Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
- Chapter 6. Global Iron Deficiency Anemia Therapy Market Size & Forecasts by Age Group 2022–2032
- 6.1. Segment Dashboard
- 6.2. Global Market: Pediatric, Adult & Geriatric Revenue Trend Analysis, 2022 & 2032 (USD Million)
- Chapter 7. Global Iron Deficiency Anemia Therapy Market Size & Forecasts by Region 2022–2032
- 7.1. North America Market
- 7.1.1. U.S. Market
- 7.1.1.1. Therapy Type breakdown size & forecasts, 2022–2032
- 7.1.1.2. End-user breakdown size & forecasts, 2022–2032
- 7.1.2. Canada Market
- 7.2. Europe Market
- 7.2.1. UK Market
- 7.2.2. Germany Market
- 7.2.3. France Market
- 7.2.4. Spain Market
- 7.2.5. Italy Market
- 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
- 7.3.1. China Market
- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
- 7.4.1. Brazil Market
- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
- 7.5.1. Saudi Arabia Market
- 7.5.2. South Africa Market
- 7.5.3. Rest of Middle East & Africa Market
- Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. Sanofi S.A.
- 8.1.2. Vifor Pharma Ltd.
- 8.1.3. Pfizer Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Sanofi S.A.
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. Vifor Pharma Ltd.
- 8.3.3. Pfizer Inc.
- 8.3.4. Daiichi Sankyo Company, Limited
- 8.3.5. AMAG Pharmaceuticals
- 8.3.6. Teva Pharmaceutical Industries Ltd.
- 8.3.7. AbbVie Inc.
- 8.3.8. F. Hoffmann-La Roche Ltd.
- 8.3.9. GlaxoSmithKline plc
- 8.3.10. Mylan N.V.
- 8.3.11. Zydus Lifesciences Ltd.
- 8.3.12. Bayer AG
- 8.3.13. Cipla Ltd.
- 8.3.14. Akebia Therapeutics, Inc.
- 8.3.15. Rockwell Medical, Inc.
- Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
- List of Tables
- TABLE 1. Global Iron Deficiency Anemia Therapy Market, report scope
- TABLE 2. Global Market estimates & forecasts by Region 2022–2032 (USD Million)
- TABLE 3. Global Market estimates & forecasts by Therapy Type 2022–2032 (USD Million)
- TABLE 4. Global Market estimates & forecasts by Age Group 2022–2032 (USD Million)
- TABLE 5. Global Market estimates & forecasts by End-user 2022–2032 (USD Million)
- TABLE 6. North America Market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 7. U.S. Market estimates & forecasts by segment 2022–2032 (USD Million)
- TABLE 8. Canada Market estimates & forecasts by segment 2022–2032 (USD Million)
- TABLE 9. Europe Market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 10. Europe Market estimates & forecasts by country 2022–2032 (USD Million)
- TABLE 11. Asia Pacific Market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 12. Asia Pacific Market estimates & forecasts by country 2022–2032 (USD Million)
- TABLE 13. Latin America Market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 14. Latin America Market estimates & forecasts by country 2022–2032 (USD Million)
- TABLE 15. Middle East & Africa Market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 16. Middle East & Africa Market estimates & forecasts by country 2022–2032 (USD Million)
- TABLE 17. Global Ferrous Sulfate vs. Parenteral Iron formulation comparison 2022–2032
- TABLE 18. Patient compliance rates by Therapy Type, 2022–2032
- TABLE 19. Revenue share of top 5 companies in 2023 (%)
- TABLE 20. R&D pipeline analysis for novel iron formulations
- List of Figures
- FIGURE 1. Global Iron Deficiency Anemia Therapy Market, research methodology
- FIGURE 2. Market estimation techniques
- FIGURE 3. Global market size estimates & forecast methods
- FIGURE 4. Key trends shaping IDA therapy in 2023
- FIGURE 5. Growth prospects 2022–2032
- FIGURE 6. Porter’s 5 Forces overview
- FIGURE 7. PESTEL analysis summary
- FIGURE 8. Value chain analysis
- FIGURE 9. Market share by Therapy Type, 2023 vs. 2032
- FIGURE 10. Market share by End-user, 2023 vs. 2032
- FIGURE 11. North America regional snapshot, 2022 & 2032
- FIGURE 12. Europe regional snapshot, 2022 & 2032
- FIGURE 13. Asia Pacific regional snapshot, 2022 & 2032
- FIGURE 14. Latin America regional snapshot, 2022 & 2032
- FIGURE 15. Middle East & Africa regional snapshot, 2022 & 2032
- FIGURE 16. Company market share analysis, 2023
- FIGURE 17. Patient adherence trends by Age Group
- FIGURE 18. Comparative cost analysis: Oral vs. Parenteral iron
- FIGURE 19. Forecast drivers heatmap
- FIGURE 20. Top growth opportunities by region
- This list is indicative; the final report contains additional tables and figures as required.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.